peptide

Axoltis misses the mark in phase 2 ALS study but will persevere with the synthetic peptide
Biotech

Axoltis misses the mark in ph. 2 ALS study, but won't give up

Axoltis' trial may have missed its key goal, but the French biotech pointed to secondary endpoints to justify persevering with the synthetic peptide.
Marissa Russo Sep 15, 2026 3:00am
Sketch of lungs

With $30M, Oorja Bio breathes new life into fibrosis candidate

May 20, 2026 10:31am
An artists concept of chains of amino acides called peptides which together make up polypeptides or proteins
Favicon Fierce Pharma

FDA advisory committee to discuss action on unapproved peptides

Apr 15, 2026 5:15pm
blocks coins money

Syneron closes $150M round to support peptide platform

Apr 3, 2026 9:31am
Close-up of shredded document

Lisata reclaims China rights to solid tumor candidate from Qilu

Jan 27, 2026 10:12am
MA

Cancer imaging company buys Lisata for ph. 2-stage tumor drug

Jan 21, 2026 9:20am